Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.

Oncology

Volumn 67, Issue 5-6, 2004, Pages 338-343

  Van Laethem, J L ^a   Van Maele, P ^a   Verslype, C ^a   Polus, M ^a   Demols, A ^a   Houbiers, G ^a   Caenepeel, P ^a   Leleux, A ^a   Vermaut, R R ^a   Van Cutsem, E ^a   Peeters, M ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GEMCITABINE; QUINAZOLINE DERIVATIVE; RALTITREXED; THIOPHENE DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BELGIUM; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PANCREAS TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BELGIUM; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; QUINAZOLINES; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 13844307892     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082916     Document Type: Article

References (0)